# University Hospital Southampton / Centre for Cancer Immunology

Source: https://onco.cc/institutions/southampton-cancer/  
OnCo record `southampton-cancer` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Southampton's university hospital and the UK's first purpose-built cancer immunology centre, known for antibody engineering and lymphoma trials.

## Summary

University Hospital Southampton is the tertiary cancer centre for central southern England, and the University of Southampton opened the Centre for Cancer Immunology in 2018, describing it as the UK's first dedicated centre of its kind. Martin Glennie and Mark Cragg's antibody groups defined how Fc receptors and antibody isotype govern anti-CD20, anti-CD40 and other immunomodulatory antibodies, and Peter Johnson led the RATHL trial that established PET-adapted treatment for advanced Hodgkin lymphoma. The Southampton Clinical Trials Unit and CRUK Southampton Centre run national trials in lymphoma, lung and gastrointestinal cancers and in DNA and peptide vaccines. The hospital houses a large children's oncology service and a Wessex regional genomics laboratory.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: UHS; Southampton Centre for Cancer Immunology; CRUK Southampton Centre
- City: Southampton, GB
- Type: hospital
- Website: https://www.uhs.nhs.uk/

## Sources

- UHS cancer services (page moved; nearest live section): https://www.uhs.nhs.uk/
- Centre for Cancer Immunology: https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [FDG PET](https://onco.cc/technologies/fdg-pet/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- targets: [CD20](https://onco.cc/targets/cd20/)
- institutions: [AMMF, the Cholangiocarcinoma Charity](https://onco.cc/institutions/ammf/), [Cancer Research UK](https://onco.cc/institutions/cruk/), [Wessex Cancer Alliance](https://onco.cc/institutions/wessex-cancer-alliance/)
- terms: [ADCC (antibody-dependent cellular cytotoxicity)](https://onco.cc/terms/adcc/), [Fc engineering / effector function](https://onco.cc/terms/fc-effector/)
- people: [Ellen Copson](https://onco.cc/people/ellen-copson/), [John N. Primrose](https://onco.cc/people/john-primrose/), [Peter Johnson](https://onco.cc/people/peter-johnson/)
- trials: [EUROPAC](https://onco.cc/trials/europac/), [Precision-Panc](https://onco.cc/trials/precision-panc/)
- collections: [UK specialist HPB cancer centres](https://onco.cc/collections/uk-hpb-specialist-centres/)

---
JSON: https://onco.cc/api/v1/entities/southampton-cancer.json